Aeglea BioTherapeutics, Inc.’s $60 Million Common Stock And Pre-Funded Warrants Offering

Ambrogio Visconti

Davis Polk advised the joint book-running managers in connection with a $60 million SEC-registered common stock and pre-funded warrants offering by Aeglea BioTherapeutics, Inc. The common…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

…

This content is for Standard 1 Year members only.
Login Join Now